Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
Matteo S. Carlino(The University of Sydney), Adil Daud(University of California, San Francisco), Christian Caglevic, Pascal Wolter(KU Leuven), Catherine Barrow, Marta Nyakas(Oslo University Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Nageatte Ibrahim(Merck & Co., Inc., Rahway, NJ, USA (United States)), Ahmed Tarhini(University of Pittsburgh), Christoph Höeller(Medical University of Vienna), Kenneth Emancipator(Merck & Co., Inc., Rahway, NJ, USA (United States)), Georgina V. Long(The University of Sydney), Gil Bar‐Sela(Emek Medical Center), Antoni Ribas(University of California, Los Angeles), Christian U. Blank(The Netherlands Cancer Institute), Caroline Robert(Institut Gustave Roussy), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Erin Jensen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Erika Richtig(Medical University of Graz)
Cited by 98
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k